Pegvisomant monotherapy once daily returns concentrations of insulin-like growth factor I (IGF-I) to normal in most patients with acromegaly, but is very costly. In a 42-week dose-finding study, we assessed the efficacy of the combination of long-acting somatostatin analogues once monthly and pegvisomant once weekly in 26 patients with active acromegaly. Dose of pegvisomant was increased until IGF-I concentration became normal or until a weekly dose of 80 mg was reached. IGF-I reached normal concentrations in 18 of 19 (95%) patients who completed 42 weeks of treatment, with a median weekly dose of 60 mg pegvisomant (range 40-80). No signs of pituitary tumour growth were noted, but mild increases in liver enzymes were observed in ten patients (38%). This combined treatment is effective, might increase compliance, and could greatly reduce the costs of medical treatment for acromegaly in some patients.

Additional Metadata
Persistent URL dx.doi.org/10.1016/S0140-6736(05)63011-5, hdl.handle.net/1765/56859
Journal The Lancet
Citation
Feenstra, J, de Herder, W.W, ten Have, S.M.T.H, van den Beld, A.W, Feelders, R.A, Janssen, J.A.M.J.L, & van der Lely, A-J. (2005). Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. The Lancet, 365(9471), 1644–1646. doi:10.1016/S0140-6736(05)63011-5